Drugs / Lenograstim
Lenograstim
also known as
Granocyte · G-CSF · G-csf (cho cell derived) · Glycosylated recombinant g-csf · Granocyte-13 · Granocyte-34 · GRANOGYTE 34 · Granulocyte colony-stimulating factor lenograstim · +5 more
Protein / enzyme biologic targets CSF3R via activation
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02502747 | Jan 2020 → Oct 2021 | heart failure, myocardial infarction | Catholic University of the Sacred Heart | Withdrawn | No outcome recorded |
| Phase 2 | NCT01302171 | Aug 2010 → Dec 2012 | dilated cardiomyopathy | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01085058 | May 2003 → Dec 2004 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | WiSP Wissenschaftlicher Service Pharma GmbH | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01107756 | Mar 2010 → Jul 2012 | neoplasm | Sanofi | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05296317 | Sep 2022 → Sep 2025 | breast carcinoma | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| — | NCT03498248 | Feb → Aug 2018 | neutropenia | DERSHENG SUN | Unknown | No outcome recorded |
| — | NCT02184897 | Jul 2014 → Aug 2016 | plasma cell myeloma | Asan Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy14 trials | ||||||
| Phase 1 | NCT05594433 Background | Sep 2015 → Dec 2024 overdue | — | CellProthera | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00551122 Background | Nov 2006 → Apr 2013 | central nervous system neoplasm, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor | University of Southampton | Unknown | No outcome recorded |
| Phase 1/2 | NCT00379574 Background | Sep 2006 → Jan 2011 | diffuse large B-cell lymphoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01180322 Background | Nov 2010 → Jun 2012 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 2/3 | NCT01907009 Background | Jan 2013 → Dec 2016 | castration-resistant prostate carcinoma | Barts & The London NHS Trust | Terminated | No outcome recorded |
| Phase 2/3 | NCT00650143 Comparator | Mar 2008 → Jun 2012 | acute myocardial infarction | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT02961257 Background | May 2017 → Dec 2021 | metastatic prostate carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Completed | No outcome recorded |
| Phase 3 | NCT02319135 Comparator | Oct 2014 → Oct 2018 | acute myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01827605 Background | Jan 2012 → Oct 2019 | follicular lymphoma | Fondazione Italiana Linfomi - ETS | Completed | Missed primary |
| Phase 3 | NCT00499018 Background | Jan 2006 → Jun 2011 | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | Met primary |
| Phase 3 | NCT00932217 Comparator | Dec 2004 → Apr 2007 | — | University of Pisa | Unknown | No outcome recorded |
| Phase 3 | NCT00431080 Background | Aug 2004 → Oct 2007 | breast cancer | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 4 | NCT06145321 Background | Nov 2023 → Nov 2024 overdue | childhood malignant neoplasm, neutropenia | Chang Gung Memorial Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT00487448 Background | Jul 1998 → May 2007 | acute myeloid leukemia, myelodysplastic syndrome | PETHEMA Foundation | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-20 | Chugai Pharmaceutical | Chugai Obtains Partial Change Approval for Neutrogin and Avastin Based on Public Knowledge-based Applications chugai-pharm.co.jp ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lenograstim | “Lenograstim (rhu G-CSF, Myelostim 34, Italfarmaco) (5 µg/kg twice daily for 5 days, subcutaneously) or placebo (saline solution twice daily for 5 days, subcutaneously) will be...” NCT02502747 ↗18“FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin” NCT00487448 ↗ “day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc” NCT01827605 ↗ “Lenograstim, Granocyte™, Chugai Pharma UK, Limited” NCT01302171 ↗ “Filgrastim, Lenograstim” NCT06145321 ↗ |
| Known as | G-CSF | “FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin” NCT00487448 ↗ |
| Known as | G-csf (cho cell derived) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | Glycosylated recombinant g-csf | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | Granocyte | “Prophylactic G-CSF (GRANOCYTE) will be injected from Day 3 to Day 7 after every administration cycle of cabazitaxel” NCT02961257 ↗4“glycosylate G-CSF (lenograstim, Granocyte®)10 µg/kg/d SC during 5 days” NCT00487448 ↗ “Lenograstim, Granocyte™, Chugai Pharma UK, Limited” NCT01302171 ↗ “Lenograstim (GRANOCYTE)=GCSF” NCT00650143 ↗ “Granocyte” NCT00431080 ↗ |
| Known as | Granocyte-13 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | Granocyte-34 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | GRANOGYTE 34 | “LENOGRASTIM (GRANOGYTE 34)” NCT01107756 ↗ |
| Known as | Granulocyte colony-stimulating factor lenograstim | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | Lenograstim (genetical recombination) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | Lenograstim rdna | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | Myelostim 34 | “Lenograstim (rhu G-CSF, Myelostim 34, Italfarmaco) (5 µg/kg twice daily for 5 days, subcutaneously) or placebo (saline solution twice daily for 5 days, subcutaneously) will be...” NCT02502747 ↗ |
| Known as | Neutrogin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109128 ↗ |
| Known as | rhu G-CSF | “Lenograstim (rhu G-CSF, Myelostim 34, Italfarmaco) (5 µg/kg twice daily for 5 days, subcutaneously) or placebo (saline solution twice daily for 5 days, subcutaneously) will be...” NCT02502747 ↗ |
| Action | Activate | “Granulocyte colony stimulating factor receptor agonist” CHEMBL2109128 ↗ |
| Modality | Protein / enzyme biologic | “granulocyte colony-stimulating factor (G-CSF)” PMID 21163927 ↗ Dec 2010 |
| Route | Subcutaneous | “Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks” NCT00379574 ↗ |
| Target | CSF3R | “Granulocyte colony stimulating factor receptor agonist” CHEMBL2109128 ↗ |